H2-blocker
Showing 1 - 25 of >10,000
Glycogen Storage Disease Type III Trial in Worldwide (biological, other, drug)
Recruiting
- Glycogen Storage Disease Type III
- UX053
- +4 more
-
Orange, California
- +9 more
Jul 22, 2022
Bismuth for PCAB-based H. Pylori Eradication
Recruiting
- H. Pylori Infection
- H. pylori eradication
-
Seoul, Korea, Republic ofDigestive Disease Center, Soonchunhyang University Hospital
Jul 7, 2022
Diabetic Macular Edema, Diabetic Retinopathy Trial in Querétaro City, Queretaro (DME lactose pill, DME levosulpiride, DR lactose
Recruiting
- Diabetic Macular Edema
- Diabetic Retinopathy
- DME lactose pill
- +7 more
-
Querétaro City, Queretaro, Mexico
- +1 more
Oct 31, 2022
Exercise, Histamine Trial in Ghent (Placebo: Placebo + exercise training., H1 blockade: H1 receptor antagonist + exercise
Active, not recruiting
- Exercise
- Histamine
- Placebo: Placebo + exercise training.
- +2 more
-
Ghent, Oost-Vlaanderen, BelgiumDepartment of movement and sports sciences, Ghent University, Be
Nov 8, 2022
Visual Acuity Trial in United States (TRP-200, JJVC Marketed Contact Lens)
Completed
- Visual Acuity
- TRP-200
- JJVC Marketed Contact Lens
-
Jacksonville, Florida
- +11 more
Dec 9, 2021
Thoracic Surgery, Lung Isolation Trial in Toronto (Double lumen tube, Fuji blocker, EZ blocker)
Completed
- Thoracic Surgery, Lung Isolation
- Double lumen tube
- +2 more
-
Toronto, Ontario, CanadaToronto General Hospital, 200 Elizabeth St.
Apr 29, 2021
COVID-19, SARS-CoV2 Infection Trial in India (Candesartan Cilexetil, Repagermanium, Candesartan Placebo)
Recruiting
- COVID-19
- SARS-CoV2 Infection
- Candesartan Cilexetil
- +3 more
-
Guntur, India
- +4 more
Mar 13, 2022
Heart Failure Trial (SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First)
Not yet recruiting
- Heart Failure
- SGLT2i, beta blocker, ARNI, MRA, MTD
- Education-First
- (no location specified)
Feb 9, 2023
Awareness, Mechanical Ventilation, Intubation Complication Trial in United States (Standard neuromuscular blocker practices,
Not yet recruiting
- Awareness
- +3 more
- Standard neuromuscular blocker practices
- Education
-
Iowa City, Iowa
- +3 more
Sep 6, 2022
Healthy Trial in Madison (Selpercatinib, Ranitidine, Omeprazole)
Completed
- Healthy
- Selpercatinib
- +2 more
-
Madison, WisconsinCovance Clinical Research Unit, Inc.
Jan 12, 2023
Alzheimer Trial in Wonju (H2 gas inhalation)
Completed
- Alzheimer Disease
- H2 gas inhalation
-
Wonju, Ganwon-do, Korea, Republic of
- +1 more
Jun 6, 2023
Therapeutic Drug Use for CKD Patients
Active, not recruiting
- Chronic Kidney Disease
- angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, calcium channel blockers, β Receptor blocker
-
Jinan, Shandong, ChinaXiao Li，MD
Apr 18, 2023
Treatment of Resistant Hypertension: Cohort Study
Recruiting
- Resistant Hypertension
- Add-on therapy
-
Belgrade, Serbia
- +11 more
Oct 21, 2021
Stroke, Ischemic Trial in Stony Brook (Hydrogen, Minocycline, Placebo Hydrogen)
Recruiting
- Stroke, Ischemic
- Hydrogen
- +3 more
-
Stony Brook, New YorkStony Brook University Hospital
Nov 14, 2022
Adolescent Behavior Trial in Murcia (Intensive high intensity intervallic training group, Extensive high-intensity intervallic
Enrolling by invitation
- Adolescent Behavior
- Intensive high intensity intervallic training group
- Extensive high-intensity intervallic training
-
Murcia, SpainNoelia G González-Gálvez, PhD.
Sep 14, 2022
Ards Trial in Medan
Completed
- Ards
-
Medan, SUmatera UTara, IndonesiaRSUP H. ADam Malik
Oct 25, 2023
Stable Ischemic Heart Disease, Coronary Artery Disease, Beta-blocker Therapy Trial in Edmonton (Medical Assessment, Quality of
Recruiting
- Stable Ischemic Heart Disease
- +2 more
- Medical Assessment
- Quality of Life Assessment
-
Edmonton, Alberta, CanadaUniversity of Alberta Hospital
Jan 30, 2023
Myocardial Infarction Trial in Italy, Spain (Beta blocker)
Recruiting
- Myocardial Infarction
- Beta blocker
-
San Severo, Foggia, Italy
- +103 more
Mar 24, 2022
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Buffalo (behavioral, drug, other)
Recruiting
- Plasma Cell Myeloma
- +3 more
- Behavioral Intervention
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 5, 2022
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2
Recruiting
- Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
-
Duarte, California
- +12 more
Jul 6, 2022
Influenza, Human, Infections, Respiratory Tract Infections Trial in Philippines, United States (Low dose A/H2N3c + standard dose
Not yet recruiting
- Influenza, Human
- +4 more
- Low dose A/H2N3c + standard dose MF59
- +5 more
-
Rockville, Maryland
- +7 more
May 26, 2023
Protamine Adverse Reaction Trial in Bangkok (Chlorpheniramine and ranitidine, 0.9% Normal Saline)
Completed
- Protamine Adverse Reaction
- Chlorpheniramine and ranitidine
- 0.9% Normal Saline
-
Bangkok, ThailandSiriraj Hospital
Aug 31, 2021
Pulse Oximetry With Different Oximeters and Arterial Saturation:
Not yet recruiting
- Respiratory Failure
- +2 more
- SpO2 and SaO2 comparison
-
Montréal, Quebec, Canada
- +2 more
Oct 25, 2023